Edition:
India

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

251.10INR
22 Nov 2019
Change (% chg)

Rs-3.30 (-1.30%)
Prev Close
Rs254.40
Open
Rs254.35
Day's High
Rs256.35
Day's Low
Rs247.55
Volume
1,370,223
Avg. Vol
1,459,541
52-wk High
Rs369.00
52-wk Low
Rs206.50

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Says Zydus Announces Second Phase 3 Trial Of Desidustat
Monday, 18 Nov 2019 

Nov 18 (Reuters) - Cadila Healthcare Ltd ::ZYDUS ANNOUNCES SECOND PHASE 3 TRIAL OF DESIDUSTAT.  Full Article

Cadila Healthcare Buys 15% Stake In Zydus Technologies
Wednesday, 13 Nov 2019 

Nov 13 (Reuters) - Cadila Healthcare Ltd ::ACQUIRED 15% EQUITY SHARE CAPITAL OF ZYDUS TECHNOLOGIES.ALSO ACQUIRED 15% COMMON STOCK OF ZYDUS NOVELTECH INC., USA.  Full Article

Cadila Healthcare Says Zydus Gets Final USFDA Nod For Cisatracurium Besylate Injection USP
Tuesday, 5 Nov 2019 

Nov 5 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR CISATRACURIUM BESYLATE INJECTION USP.DRUG WILL BE MANUFACTURED AT UNIT LIVA PHARMACEUTICALS.  Full Article

Cadila Healthcare Gets Warning Letter Issued By US FDA Relating To Moraiya Formulation Facility
Monday, 4 Nov 2019 

Nov 4 (Reuters) - Cadila Healthcare Ltd ::. - WARNING LETTER - US FDA.SAYS COMPANY HAS RECEIVED A WARNING LETTER ISSUED BY US FDA RELATING TO ITS MORAIYA FORMULATION FACILITY..WARNING LETTER RELATING TO ITS MORAIYA FORMULATION FACILITY.WILL CONTINUE TO TAKE NECESSARY STEPS TO ENSURE THAT US FDA IS FULLY SATISFIED WITH REMEDIATION OF ABOVE FACILITY.CONFIDENT OF RESPONDING TO US FDA TO ADDRESS THE OBSERVATIONS WITHIN THE STATUTORY TIME.CADILA HEALTHCARE -WARNING LETTER DOES NOT AFFECT EXISTING BUSINESS OF CO IN US AND THE EXISTING PRODUCT SUPPLIES FROM MORAIYA FACILITY TO CONTINUE..  Full Article

Cadila Healthcare Says API Manufacturing Facility At Dabhasa Completes U.S. FDA Inspection
Friday, 11 Oct 2019 

Oct 11 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE LTD - API MANUFACTURING FACILITY AT DABHASA SUCCESSFULLY COMPLETES USFDA INSPECTION.  Full Article

Cadila Gets US FDA's 'NAI' Classification For Ankleshwar Plant
Monday, 23 Sep 2019 

Sept 23 (Reuters) - Cadila Healthcare Ltd ::SAYS US FDA EIR REPORT CLASSIFIED ANKLESHWAR FACILITY AS 'NO ACTION INDICATED'.SHARES RISE 2% AFTER US FDA SAYS 'NO ACTION INDICATED' FOLLOWING INSPECTION AT ANKLESHWAR PLANT.  Full Article

Cadila Healthcare Says U.S. FDA Classifies Co's Moraiya Facility As OAI
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Cadila Healthcare Ltd ::GETS LETTER FROM U.S. FDA CLASSIFYING INSPECTION AT CO'S MORAIYA FACILITY AS 'OFFICIAL ACTION INDICATED' (OAI).CLASSIFICATION WILL NOT HAVE ANY IMPACT ON CURRENT SUPPLIES OR REVENUES OF FACILITY.IN PROCESS OF SENDING FURTHER UPDATES OF ITS CORRECTIVE ACTIONS TO U.S. FDA.  Full Article

Cadila Healthcare Says U.S. FDA Inspects Co's API Manufacturing Facility At Ankleshwar
Friday, 26 Jul 2019 

July 26 (Reuters) - Cadila Healthcare Ltd ::SAYS USFDA INSPECTED CO'S API MANUFACTURING FACILITY LOCATED AT ANKLESHWAR.SAYS AT END OF INSPECTION, NO OBSERVATION (483) IS ISSUED.  Full Article

India's Cadila Healthcare March-Qtr Consol Net Profit Falls
Wednesday, 29 May 2019 

May 29 (Reuters) - Cadila Healthcare Ltd ::MARCH QUARTER CONSOL NET PROFIT 4.6 BILLION RUPEES VERSUS PROFIT OF 5.91 BILLION RUPEES LAST YEAR.MARCH QUARTER CONSOL SALES 36.2 BILLION RUPEES VERSUS 31.53 BILLION RUPEES LAST YEAR.RECOMMENDED DIVIDEND OF 3.5 RUPEES PER SHARE.  Full Article

Cadila Healthcare Says USFDA Inspection At Moraiya Formulations Manufacturing Facility Ended With 14 Observations
Friday, 3 May 2019 

May 3 (Reuters) - Cadila Healthcare Ltd ::USFDA INSPECTED COMPANY'S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD FROM 22ND APRIL 2019 TO 3RD MAY 2019.SAYS INSPECTION CONCLUDED WITH 14 OBSERVATIONS.THERE WERE NO REPEAT OBSERVATIONS OR DATA INTEGRITY RELATED OBSERVATIONS.  Full Article